Pharmacokinetics of high-dose oseltamivir in healthy volunteers. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

http://www.wikidata.org/entity/Q37115683

about

Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance What is the optimal therapy for patients with H5N1 influenza?I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation.Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.Oseltamivir in human avian influenza infection.Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.Laboratory capacity building in Asia for infectious disease research: experiences from the South East Asia Infectious Disease Clinical Research Network (SEAICRN)The mechanisms of sudden-onset type adverse reactions to oseltamivir.Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.Effects of alcohol on human carboxylesterase drug metabolism.Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Optimizing antiviral therapy for influenza: understanding the evidence.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population.Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.Sequence diversity of NanA manifests in distinct enzyme kinetics and inhibitor susceptibility.Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets.Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling Oseltamivir Dosing in Critically Ill Patients With Severe Influenza.Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.

P2860

Q24630906-2D42A584-655E-4C5C-9099-C1CBD83504C2 Q27317735-BE143304-16C3-469A-9234-98D727136054 Q27663966-C60746D5-DD54-4025-86F8-5FD3722F5873 Q28282405-29378C1F-67EC-4C21-8118-9420BBAAA3FB Q28475630-92CAE600-22DA-431E-8160-298D81405601 Q28533778-DA1CD841-D471-4813-87E2-CE0324D06DBA Q28537982-5F81A359-1B0D-4037-91FA-7F73026FC8E1 Q30357189-1866042D-AEEC-4784-9B17-B1BA8A055868 Q30357472-FC92ED60-074D-48F8-B535-B2F766E01035 Q30373969-5C5268F4-CBC9-44F9-A5DE-455FA5EDEF81 Q30385708-EEFBAA36-A0D2-418B-A094-E85610C531E2 Q30386487-C899C363-F593-493D-A260-8CC1A90E019D Q30390145-DD33E5DF-39E5-4B5C-B8B8-78DA60B25799 Q30390856-2C8FED75-EC2E-47F2-B40C-624BF2B6C605 Q33553385-87199C28-F85B-4FDA-BC7F-559098F47E59 Q34677701-34AFDA88-C127-470F-8B58-0C3DA3157510 Q35191579-A0E0C688-CBDF-4C5F-82F1-6710B70A4296 Q35191600-9F2B45ED-AC28-43A4-94D4-710C3C03ED5B Q35668517-5DF3B16E-12AB-4045-9142-282A1395FB2F Q35860081-A133681A-1548-45B4-A2B6-601C2DAEB4AB Q36468109-8C7DE048-B6DA-400C-9045-158D63F57EC2 Q36505517-4E178FBF-508B-48AB-9036-05BCF150D5B6 Q36924693-9358F85B-A32D-45ED-9508-3DFF4D1250A8 Q37026673-460A8D8D-8AFC-4B24-B825-2B44ED71F0A1 Q37394266-9ED913E7-513C-416D-923E-E24BAB80449B Q37409972-6D83871A-AC0A-41A3-9969-F6FDF217CC59 Q38084212-FAD0D4C8-A32A-44BF-B346-06CBC3D286D1 Q38361244-321E8900-3E0E-4106-8A3A-754B6B7E8FB4 Q38790740-6CC36CF4-9164-422F-9955-44EC6717555D Q39147483-8D3CAD7D-8199-49B2-8334-6D6512E0AC92 Q39404447-A6606328-467B-4C42-83B3-5DF7089D0249 Q39592863-FDF6E840-7B70-4908-B00C-9ED928A19E6F Q40734518-7E9943F7-E8D2-43D3-9B78-40A16456BE89 Q40748977-B8C0B4C8-FD47-42CC-85C5-54B7981F438F Q40777377-E1262466-38C4-4119-B17E-19E0E5764EEA Q41123104-02600244-DC69-485B-85FB-11CB782F5760 Q41285709-769781FD-1205-4A18-9AEB-0B280AAE2F3C Q41745036-CDF13D70-669F-4799-B954-F94AF4855ADF Q44857539-EDB9ABDD-4868-431B-A881-F4446602D0F4 Q53351375-BB0D5A05-E2EB-4443-86EC-57CC2CFE448A

P2860

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

http://www.wikidata.org/entity/Q37115683

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

@en

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

@nl

type

label

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

@en

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

@nl

prefLabel

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

@en

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

@nl

P1433

Q37115683-DC7E34A4-F598-4042-8B2D-D2900DCFCDFD

P1476

Q37115683-DF450883-CA21-43A5-9DED-E9ABB4AABFF7

P2093

Q37115683-1FAC34FC-92CD-49AD-BD69-274044CCC3FF

Q37115683-3DF5538B-4068-4EB3-AB5F-56CAE6E7F9FE

Q37115683-4886E508-AA1D-435F-8B3F-9EA55C1AB7EA

Q37115683-7898331D-E0E6-4546-AF75-5301C032914F

Q37115683-897DAE00-CD54-441B-A056-02DF7A3DCFDC

Q37115683-903C4B9C-3EB0-4F36-8753-A4423CAF7B86

Q37115683-A3A9771D-F278-40B4-9C6F-91B84819DEE1

Q37115683-B0FEB203-9D16-4F30-9B29-0F414D4BA98B

Q37115683-B88629CC-A766-44B0-A290-C23A63F8CC22

Q37115683-CD48052A-7E01-4993-82B4-A800FC8A89EF

P2860

Q37115683-071258A6-9DEE-4FE8-98B9-298F30219BF5

Q37115683-13F16D55-EEED-4F37-9CCC-00C58AD0AF5A

Q37115683-18955F51-ECC5-44C0-9243-6F9227F818A5

Q37115683-1A963E46-BD5D-4874-9309-FA37A650A1F2

Q37115683-21BD7EAC-19F3-4EFE-95EF-6BB78AAD1787

Q37115683-257C80F2-E013-4A6E-976B-0C5B4672129D

Q37115683-2BCA04C5-A249-4D93-BA59-D84DD6D1D44E

Q37115683-4554C491-A9D6-46F9-B02A-B9EF9058679D

Q37115683-47854AC9-21BE-41FA-B5B9-6E3EB8422098

Q37115683-527F5BC6-12CF-4AEC-BFE8-C6D5148B22A7

P304

Q37115683-1FD234D3-A6F8-4EEE-B97C-24E9488F1655

P31

Q37115683-E91EDFEB-B52E-4E4B-B141-D2BB2C8DC842

P356

Q37115683-2693179E-D612-4733-A165-49B75C8ADEBB

P407

Q37115683-60E0B346-1B31-448F-A19F-8BCB550A745B

P433

Q37115683-32F8D0F8-638A-4CA4-B055-4CDF7FA52B88

P478

Q37115683-4A836696-D4AD-47B2-8AEF-1F8BBF14693F

P50

Q37115683-56D5B521-02C4-4E12-AA07-D6E423FCC09A

Q37115683-8AFA25B4-BDB2-49BA-B188-632AD52D57AC

Q37115683-C106250B-BDE2-43CE-A469-08E6A3E678A5

P577

Q37115683-DED69528-428E-4A90-A746-B57DD47CC53F

P698

Q37115683-5D13644B-3140-426F-806C-AA497A68D8E1

P932

Q37115683-72E4F0D0-D2EC-47F6-8280-812C7E1A52AA

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

@en

P2093

C Fukuda

http://www.w3.org/2001/XMLSchema#string

G Davies

http://www.w3.org/2001/XMLSchema#string

J Tarning

http://www.w3.org/2001/XMLSchema#string

K Stepniewska

http://www.w3.org/2001/XMLSchema#string

N Lindegårdh

http://www.w3.org/2001/XMLSchema#string

S Pukrittayakamee

http://www.w3.org/2001/XMLSchema#string

T Singtoroj

http://www.w3.org/2001/XMLSchema#string

U Silachamroon

http://www.w3.org/2001/XMLSchema#string

W Hanpithakpong

http://www.w3.org/2001/XMLSchema#string

W Piyaphanee

http://www.w3.org/2001/XMLSchema#string

P2860

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

Update on avian influenza A (H5N1) virus infection in humans

A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination

Rational design of potent sialidase-based inhibitors of influenza virus replication

Oseltamivir resistance during treatment of influenza A (H5N1) infection

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.

Immuno-histochemical detection of MRPs in human lung cells in culture.

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.

P304

945-952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00588-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas John White

Nicholas P J Day

Pratap Singhasivanon

P577

2008-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19104028

http://www.w3.org/2001/XMLSchema#string

P932

2650521

http://www.w3.org/2001/XMLSchema#string